INAB (IN8bio) Forward Dividend Yield %: 0.00% (As of Jun. 28, 2026)


INAB IN8bio Inc INAB
24 GF Score
Price $1.36
View Full Analysis

What is IN8bio Forward Dividend Yield %?

IN8bio INAB -0.45% 24 Forward Dividend Yield % is 0.00% as of Jun. 28, 2026. GuruFocus rates INAB with a GF Score™ of 24/100. Among 145 Biotechnology companies, IN8bio ranks worse than 689654.48% on this metric.

As of today (2026-06-28), the Forward Annual Dividend Yield of IN8bio is 0.00%.

As of today (2026-06-28), the Trailing Annual Dividend Yield of IN8bio is 0.00%.

INAB's Forward Dividend Yield % is not ranked *
in the Biotechnology industry.
Industry Median: 1.57
* Ranked among companies with meaningful Forward Dividend Yield % only.

IN8bio's Dividends per Share for the three months ended in Mar. 2026 was $0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

IN8bio  (NAS:INAB) Forward Dividend Yield % Explanation

Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.

Dividends may also qualify a lower tax rate for investors.

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.

IN8bio Forward Dividend Yield % Related Terms

INAB vs ZIVO, LPCN, CTXR: Forward Dividend Yield % Comparison

For the Biotechnology subindustry, IN8bio's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

IN8bio Forward Dividend Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, IN8bio's Forward Dividend Yield % distribution charts can be found below:

* The bar in red indicates where IN8bio's Forward Dividend Yield % falls into.


INAB
24GF Score
IN8bio Inc INAB
Forward Dividend Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

IN8bio Forward Dividend Yield % Calculation

Dividend Yield measures how much a company pays out in dividends each year relative to its share price.

What does a Forward Dividend Yield % of 0.00% mean?
IN8bio (INAB) has a Forward Dividend Yield % of 0.00% as of Jun. 28, 2026. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on IN8bio and its competitors. According to the industry distribution chart, IN8bio ranks #999999 out of 145 companies in the Biotechnology industry.
Is IN8bio's Forward Dividend Yield % too high?
IN8bio's current Forward Dividend Yield % is 0.00%. Based on the distribution chart, IN8bio ranks #999999 out of 145 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, IN8bio has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does IN8bio's Forward Dividend Yield % compare to ZIVO and LPCN?
According to the Biotechnology industry distribution chart, IN8bio ranks #999999 out of 145 companies for Forward Dividend Yield %. This places IN8bio in the lower half of its industry. The industry median Forward Dividend Yield % is 1.57. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward Dividend Yield % for a Biotechnology company?
The median Forward Dividend Yield % among Biotechnology companies is 1.57, based on 145 companies in the industry. Companies in the top quartile (top 25%) have a Forward Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Forward Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward Dividend Yield % mean?
A high Forward Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on IN8bio and its competitors. For the Biotechnology industry, the median Forward Dividend Yield % is 1.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. IN8bio's current Forward Dividend Yield % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IN8bio stock overvalued right now?
IN8bio (INAB) has a current Forward Dividend Yield % of 0.00%. The current Forward Dividend Yield % is 0.00%. IN8bio's overall GF Score™ is 24/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward Dividend Yield % calculated?
Forward Dividend Yield % is calculated from a company's financial statements. For IN8bio (INAB), the current Forward Dividend Yield % is 0.00% as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

IN8bio Business Description

Address 350 5th Avenue, Suite 5330, New York, NY, USA, 10118
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cellular therapy product candidates and gamma-delta T cell engagers (TCEs) for cancer and autoimmune diseases. Gamma-delta T cells are a specialized population of T cells that possess properties. It has conducted two primary investigator-sponsored Phase 1 clinical trials evaluating its gamma-delta T cell technologies in cancer patients, which have both completed primary enrollment. INB-100 is assessing its DeltEx Allogeneic (Allo) gamma-delta T cell therapy in adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation (HSCT). It operates in a single segment.
24GF Score

Get the complete analysis for INAB

Forward Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.36
Price